ANI Pharmaceuticals (ANIP) Earnings Call Presentation

Financial Performance and Guidance - ANI Pharmaceuticals projects net revenues of $768 million to $793 million for 2025, representing a year-over-year growth of 25% to 29%[10] - The company anticipates adjusted non-GAAP EBITDA of $195 million to $205 million in 2025[10] - Adjusted non-GAAP diluted EPS is expected to be between $627 and $662 in 2025[26] - Generics revenue in Q1 2025 reached $99 million, up 41% year-over-year and 26% quarter-over-quarter[69, 70] Rare Disease Business - Cortrophin Gel net revenue is projected to be $265 million to $274 million in 2025, a 34% to 38% increase from 2024[26] - ILUVIEN and YUTIQ net revenue is expected to be $97 million to $103 million in 2025[26] - Acute gouty arthritis flares now account for approximately 18% of Cortrophin Gel usage[23] Strategic Focus and Operations - Approximately 95% of total company revenues are from products sold in the U S [10] - Over 90% of total company revenues are sourced from finished goods manufactured in the U S [10] - The company has $150 million in cash as of March 31, 2025[10]